Evidence map›Paper›PMID 31322195›Full record

ArticleMolecular medicine reports2019

Identification of a key candidate gene‑phenotype network mediated by glycyrrhizic acid using pharmacogenomic analysis.

Shiqun Wang, Lu Li, Long Shi

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shiqun WangXiaoshan Biotechnology Center, Yangtze Delta Region Institute of Tsinghua University, Hangzhou, Zhejiang 311231, P.R. China.
Lu LiDepartment of Nephrology, Affiliated Children's Hospital of Zhejiang University, Hangzhou, Zhejiang 310052, P.R. China.
Long ShiXiaoshan Biotechnology Center, Yangtze Delta Region Institute of Tsinghua University, Hangzhou, Zhejiang 311231, P.R. China.
Tsinghua University · CNChildren's Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycyrrhizic acid (GA) is primarily used as an anti‑inflammatory agent in cases of chronic hepatitis. However, its underlying mechanisms in diverse biological processes and its reported benefits are yet to be fully elucidated. In the current study, an analytical method based on pharmacogenomics was established to mine disease‑modulatory activities mediated by GA. Five primary protein targets and 138 functional partners were identified for GA by querying open‑source databases, including Drugbank and STRING. Subsequently, GA‑associated primary and secondary protein targets were integrated into Cytoscape to construct a protein‑protein interaction network to establish connectivity. GA‑associated target genes were then clustered based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The tumor necrosis factor axis was revealed to be a primary module regulated by GA‑associated targets. Furthermore, 12 hub genes were queried to assess their potential anti‑cancer effects using cBioPortal. The results indicated that pharmacogenomics‑based analysis improved understanding of the underlying drug‑target events of GA and provided predictive and definitive leads for future studies.

Indexed as

Anti-Inflammatory AgentsGene Expression ProfilingGene OntologyGene Regulatory NetworksGenomicsGlycyrrhizic AcidHumansPharmacogenomic TestingPhenotypeProtein Interaction MapsSignal TransductionAnti-Inflammatory AgentsGlycyrrhizic Acid

Identifiers

PMID31322195
PMCPMC6691250
OpenAlexW2962011290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.